Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3471 Target Snapshot

Human immunodeficiency virus type 1 integrase · SINGLE PROTEIN · Human immunodeficiency virus 1

Back to Search Search this target Browse approvals Evidence Card
5,082Compounds
808Assays
13Approved Drugs
8,168.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Human immunodeficiency virus type 1 integrase shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q7ZJM1. Start with HIV infection, then reuse UniProt Q7ZJM1 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with HIV infection, then reuse UniProt Q7ZJM1 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 8 linked drugs
Open source guide
Disease program
HIV infection

Human immunodeficiency virus type 1 integrase shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block. 8 linked drugs remain visible in the same block.

Start review with HIV infection because it currently carries approved-linked support. Linked drugs include BICTEGRAVIR, BICTEGRAVIR SODIUM, CABOTEGRAVIR, DOLUTEGRAVIR SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 8 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Human immunodeficiency virus type 1 integrase as ChEMBL target CHEMBL3471, mapped to UniProt Q7ZJM1. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Human immunodeficiency virus type 1 integrase
SINGLE PROTEIN · Human immunodeficiency virus 1
As of 2026-09-13
ChEMBL target ID
CHEMBL3471
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q7ZJM1
Gag-Pol polyprotein
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Human immunodeficiency virus type 1 integrase is the right protein anchor across sources, using UniProt Q7ZJM1 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why HIV infection is currently framed as approved-linked support. It currently carries 8 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameHuman immunodeficiency virus type 1 integrase
Target TypeSINGLE PROTEIN
OrganismHuman immunodeficiency virus 1
UniProtQ7ZJM1
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGag-Pol polyprotein
UniProt AccessionQ7ZJM1
Component TypeProtein
Sequence Length288 aa

Gag-Pol polyprotein

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Human immunodeficiency virus type 1 integrase, mapped to UniProt Q7ZJM1. ChEMBL maps the protein component as Gag-Pol polyprotein. Sequence length is 288 aa.

Mapped IDQ7ZJM1
Review nameHuman immunodeficiency virus type 1 integrase
OrganismHuman immunodeficiency virus 1
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Human immunodeficiency virus type 1 integrase shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
HIV infection
8 linked drugs · 8 direct · 8 efficacy
Linked drugBICTEGRAVIR
Linked drugBICTEGRAVIR SODIUM
Linked drugCABOTEGRAVIR
Linked drugDOLUTEGRAVIR SODIUM
Approved-linked Approved
HIV-1 infection
8 linked drugs · 8 direct · 8 efficacy
Linked drugBICTEGRAVIR
Linked drugBICTEGRAVIR SODIUM
Linked drugCABOTEGRAVIR
Linked drugCABOTEGRAVIR SODIUM
Approved-linked Approved
viral disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugCABOTEGRAVIR
Linked drugELVITEGRAVIR
Approved-linked Approved
immunodeficiency disease
1 linked drug · 1 direct · 1 efficacy
Linked drugRALTEGRAVIR POTASSIUM
Late clinical Phase III
AIDS
2 linked drugs · 2 direct · 2 efficacy
Linked drugBICTEGRAVIR SODIUM
Linked drugELVITEGRAVIR
Clinical signal Phase I
HIV-Associated Lipodystrophy Syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugCABOTEGRAVIR SODIUM
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with HIV infection because it currently carries approved-linked support. Linked drugs include BICTEGRAVIR, BICTEGRAVIR SODIUM, CABOTEGRAVIR, DOLUTEGRAVIR SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseHIV infection
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

13
Approved
4
Phase III
15
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC507,994.0
KI25.0
EC5091.0
KD58.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL204656 9.68 EC50 0.21 Approved
CHEMBL1229211 9.3 IC50 0.5 Approved
CHEMBL414850 9.3 IC50 0.5 Preclinical
CHEMBL3805182 9.22 IC50 0.6 Preclinical
CHEMBL3806067 9.15 IC50 0.7 Preclinical
CHEMBL4127663 9.0 EC50 1.0 Preclinical
CHEMBL4128240 9.0 EC50 1.0 Preclinical
CHEMBL2105735 9.0 IC50 1.0 Approved
CHEMBL1917873 9.0 IC50 1.0 Preclinical
CHEMBL5597897 8.85 IC50 1.4 Preclinical
Distribution

pChEMBL Value Distribution

791
5.0
591
5.5
520
6.0
389
6.5
450
7.0
412
7.5
396
8.0
100
8.5
13
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

CABOTEGRAVIR
CHEMBL2403238
Approved 2021
Properties Compare Identifier
BICTEGRAVIR
CHEMBL3989866
Approved 2018
Properties Compare Identifier
ASUNAPREVIR
CHEMBL2105735
Approved 2014
Properties Compare Identifier
DOLUTEGRAVIR
CHEMBL1229211
Approved 2013
Properties Compare Identifier
DOLUTEGRAVIR SODIUM
CHEMBL1213165
Approved 2013
Properties Compare Identifier
ELVITEGRAVIR
CHEMBL204656
Approved 2012
Properties Compare Identifier
RALTEGRAVIR
CHEMBL254316
Approved 2007
Properties Compare Identifier
RALTEGRAVIR POTASSIUM
CHEMBL518520
Approved 2007
Properties Compare Identifier
ZANAMIVIR
CHEMBL222813
Approved 1999
Properties Compare Identifier
DOXORUBICIN
CHEMBL53463
Approved 1974
Properties Compare Identifier
Assay Landscape

Assay Landscape

809
Total Assays
3,793
Tested Compounds
2
Assay Types
Binding — 799 assays, 3,793 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 640 3,104 5.7
assay format 128 298 5.8
cell-based format 31 391 7.3
Functional — 10 assays, 48 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 10 48 5.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine